{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:26:05Z","timestamp":1792794365920,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cmi.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T02:54:30Z","timestamp":1592362470000},"page":"1464-1472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":196,"title":["How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)"],"prefix":"10.1016","volume":"26","author":[{"given":"M.C.","family":"Arendrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kahlmeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Meletiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guinea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Arendrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Meletiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guinea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kahlmeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.T.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Arikan-Akdagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Barchiesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chryssanthou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"J\u00e4rv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Klimko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Kurzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lass-Fl\u00f6rl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Muehlethaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Velegraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Arikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.06.007_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11046-014-9775-z","article-title":"Antifungal susceptibility profile of cryptic species of aspergillus","volume":"178","author":"Alastruey-Izquierdo","year":"2014","journal-title":"Mycopathologia"},{"key":"10.1016\/j.cmi.2020.06.007_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/13693780801968571","article-title":"Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome","volume":"46","author":"Atkinson","year":"2008","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2020.06.007_bib3","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.01364-10","article-title":"Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots","volume":"55","author":"Arendrup","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib4","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory variability of caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","article-title":"Echinocandin resistance: an emerging clinical problem?","volume":"27","author":"Arendrup","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2020.06.007_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/myc.12170","article-title":"EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole","volume":"57","author":"Arendrup","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2020.06.007_bib7","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2020.06.007_bib8","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2020.06.007_bib9","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","article-title":"Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection","volume":"115","author":"Sipsas","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2020.06.007_bib10","first-page":"126","article-title":"Increasing incidence of Candida parapsilosis candidemia with caspofungin usage","volume":"56","author":"Forrest","year":"2008","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2020.06.007_bib11","series-title":"Fourth informational supplement. CLSI document M27-S4","article-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","year":"2012"},{"key":"10.1016\/j.cmi.2020.06.007_bib12","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1093\/jac\/dkw305","article-title":"Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12): table 1","volume":"71","author":"Chiotos","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/myc.13050","article-title":"Changing epidemiology of candidemia: increase in fluconazole-resistant Candida parapsilosis","volume":"63","author":"Mesini","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2020.06.007_bib14","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1128\/AAC.01177-15","article-title":"Candida parapsilosis resistance to fluconazole: molecular mechanisms and in\u00a0vivo impact in infected Galleria mellonella larvae","volume":"59","author":"Souza","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12879-016-1767-9","article-title":"Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit","volume":"16","author":"Pinhati","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2020.06.007_bib16","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1128\/AAC.04613-14","article-title":"Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system","volume":"59","author":"Grossman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01516-19","article-title":"Epidemiological trends of fungemia in Greece with a focus on candidemia during the recent financial crisis: a 10-year survey in a tertiary care academic hospital and review of literature","volume":"64","author":"Siopi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.06.007_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2020.06.007_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2020.06.007_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"7","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2020.06.007_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02438-19","article-title":"Rezafungin in\u00a0vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method","volume":"64","author":"Helleberg","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diagmicrobio.2014.03.004","article-title":"Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 Systemically active antifungal agents when tested against Candida spp","volume":"79","author":"Pfaller","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2020.06.007_bib24","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/AAC.06369-11","article-title":"Differential in\u00a0vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations","volume":"56","author":"Arendrup","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib25","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1128\/AAC.00123-14","article-title":"Positions and numbers of FKS mutations in Candida albicans selectively influence in\u00a0vitro and in\u00a0vivo susceptibilities to echinocandin treatment","volume":"58","author":"Lackner","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib26","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1128\/JCM.00962-16","article-title":"Identification by molecular methods and matrix-assisted laser desorption ionization-time of flight mass spectrometry and antifungal susceptibility profiles of clinically significant rare aspergillus species in a referral chest hospital in Delhi, India","volume":"54","author":"Masih","year":"2016","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2020.06.007_bib27","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/jac\/dkz258","article-title":"Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients","volume":"74","author":"Resendiz-Sharpe","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12281-012-0097-7","article-title":"Azole-resistant invasive aspergillosis: relationship to agriculture","volume":"6","author":"Stensvold","year":"2012","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.cmi.2020.06.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00073-19","article-title":"EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mold and yeast isolates","volume":"63","author":"J\u00f8rgensen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib30","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In\u00a0vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.007_bib31","doi-asserted-by":"crossref","first-page":"571.e1","DOI":"10.1016\/j.cmi.2016.01.017","article-title":"EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents","volume":"22","author":"Arendrup","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2020.06.007_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2014.01.001","article-title":"Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp","volume":"16","author":"Arendrup","year":"2013","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.cmi.2020.06.007_bib33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2020.06.007_bib34","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007)","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2020.06.007_bib35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study","volume":"38","author":"Wauters","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2020.06.007_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2020.06.007_bib37","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1111\/j.1469-0691.2012.03890.x","article-title":"European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST), Arendrup MC, et\u00a0al. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole","volume":"18","author":"Arendrup","year":"2012","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20303475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20303475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:25:32Z","timestamp":1761117932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20303475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1198743X20303475"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.06.007","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}